PMID- 34934197
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20230502
IS  - 1745-7254 (Electronic)
IS  - 1671-4083 (Print)
IS  - 1671-4083 (Linking)
VI  - 43
IP  - 5
DP  - 2022 May
TI  - GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
PG  - 1156-1166
LID - 10.1038/s41401-021-00836-9 [doi]
AB  - Nonalcoholic steatohepatitis (NASH), as a severe form of nonalcoholic fatty liver 
      disease (NAFLD), is characterized by liver steatosis, inflammation, 
      hepatocellular injury and different degrees of fibrosis. The pathogenesis of NASH 
      is complex and multifactorial, obesity and type 2 diabetes mellitus (T2DM) have 
      been implicated as major risk factors. Glucagon-like peptide-1 receptor (GLP-1R) 
      is one of the most successful drug targets of T2DM and obesity, and its peptidic 
      ligands have been proposed as potential therapeutic agents for NASH. In this 
      article we provide an overview of the pathophysiology and management of NASH, 
      with a special focus on the pharmacological effects and possible mechanisms of 
      GLP-1 mimetics in treating NAFLD/NASH, including dual and triple agonists at 
      GLP-1R, glucose-dependent insulinotropic polypeptide receptor or glucagon 
      receptor.
CI  - (c) 2021. The Author(s), under exclusive licence to CPS and SIMM.
FAU - Chen, Yan
AU  - Chen Y
AD  - Department of Pharmacology, School of Basic Medical Sciences, Fudan University, 
      Shanghai, 200032, China.
FAU - Xu, Ying-Na
AU  - Xu YN
AD  - Department of Pharmacology, School of Basic Medical Sciences, Fudan University, 
      Shanghai, 200032, China.
FAU - Ye, Chen-Yu
AU  - Ye CY
AD  - Department of Pharmacology, School of Basic Medical Sciences, Fudan University, 
      Shanghai, 200032, China.
FAU - Feng, Wen-Bo
AU  - Feng WB
AD  - Department of Pharmacology, School of Basic Medical Sciences, Fudan University, 
      Shanghai, 200032, China.
FAU - Zhou, Qing-Tong
AU  - Zhou QT
AD  - Department of Pharmacology, School of Basic Medical Sciences, Fudan University, 
      Shanghai, 200032, China.
FAU - Yang, De-Hua
AU  - Yang DH
AD  - The CAS Key Laboratory of Receptor Research and The National Center for Drug 
      Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 
      Shanghai, 201203, China. dhyang@simm.ac.cn.
AD  - Research Center for Deepsea Bioresources, Sanya, 572025, China. 
      dhyang@simm.ac.cn.
FAU - Wang, Ming-Wei
AU  - Wang MW
AD  - Department of Pharmacology, School of Basic Medical Sciences, Fudan University, 
      Shanghai, 200032, China. mwwang@simm.ac.cn.
AD  - The CAS Key Laboratory of Receptor Research and The National Center for Drug 
      Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 
      Shanghai, 201203, China. mwwang@simm.ac.cn.
AD  - Research Center for Deepsea Bioresources, Sanya, 572025, China. 
      mwwang@simm.ac.cn.
AD  - School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, 
      China. mwwang@simm.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211221
PL  - United States
TA  - Acta Pharmacol Sin
JT  - Acta pharmacologica Sinica
JID - 100956087
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Non-alcoholic Fatty Liver Disease/drug therapy
MH  - Obesity/drug therapy
PMC - PMC9061743
OTO - NOTNLM
OT  - GLP-1 mimetics
OT  - GLP-1R
OT  - GPCR
OT  - NAFLD
OT  - NASH
OT  - dual agonists
OT  - triple agonists
COIS- The authors declare no competing interests.
EDAT- 2021/12/23 06:00
MHDA- 2022/05/06 06:00
PMCR- 2023/05/01
CRDT- 2021/12/22 06:44
PHST- 2021/06/10 00:00 [received]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2021/12/23 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2021/12/22 06:44 [entrez]
PHST- 2023/05/01 00:00 [pmc-release]
AID - 10.1038/s41401-021-00836-9 [pii]
AID - 836 [pii]
AID - 10.1038/s41401-021-00836-9 [doi]
PST - ppublish
SO  - Acta Pharmacol Sin. 2022 May;43(5):1156-1166. doi: 10.1038/s41401-021-00836-9. 
      Epub 2021 Dec 21.